Open Orphan #ORPH – Notice of results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials , announces that it will release its full year results for the year ended 31 December 2021 on Tuesday 7 June 2022. Investor Presentation Yamin ‘Mo’ Khan, Chief Executive […]
UK Investor Magazine Podcast, we discuss #stagflation, Burberry #BRBY Open Orphan #ORPH & Tertiary Minerals #TYM
The UK Investor Magazine is joined by Alan Green for a rundown of key market themes and Uk equities. We start by looking at Stagflation at the implications for the UK economy and markets. Stagflation is a period of rising inflation, economic contraction, and rising unemployment. The UK satisfies the first two of these, […]
Open Orphan #ORPH – £7.3m Influenza human challenge study contract win
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £7.3m influenza human challenge study (“Study”) contract with a leading biotechnology company to test its antiviral product […]
#ORPH Open Orphan – Wellcome publication
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes a key considerations document for developing and manufacturing challenge agents published in the Wellcome Open Research Journal co-authored by Alex Mann, Senior Director of Clinical Research of hVIVOand […]
#ORPH Open Orphan – Vaccine field study contract
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO , a subsidiary of Open Orphan, has been awarded a new study with an existing Big Pharma client to act as a vaccination site for a Phase […]
#ORPH Open Orphan – Challenge virus manufacturing contract
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO , a subsidiary of Open Orphan, has signed a substantial contract with an existing top 5 global pharmaceutical client to manufacture a virus for use in human […]
#ORPH Open Orphan – Appointment of Nominated Adviser and Joint Broker
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that further to the announcements by Arden Partners Plc on 11 and 14 April 2022 regarding the loss of its Nominated Adviser status upon the completion of […]
Open Orphan #ORPH – Proposal to purchase Poolbeg Pharma shares from distribution in specie shareholders
Open Orphan (ORPH) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement dated 11 April 2022 from Poolbeg Pharma plc (“Poolbeg”), regarding a number of new investors (“New Investors”) having expressed interest in acquiring up to £1.6m of […]
Open Orphan #ORPH – Presentation at World Vaccine Congress
Presentation at World Vaccine Congress hVIVO presents on the outcomes from the world’s first COVID-19 characterisation study Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, a subsidiary of Open […]
Open Orphan #ORPH – COVID-19 Characterisation Study peer reviewed results published in industry leading periodical Nature Medicine
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that the results from the world’s first COVID-19 characterisation study have been peer reviewed and published in the scientific journal Nature Medicine. ‘Safety, tolerability and viral kinetics […]